Equities

National Research Corp

National Research Corp

Actions
Health CareHealth Care Providers
  • Price (USD)34.87
  • Today's Change-0.10 / -0.29%
  • Shares traded55.55k
  • 1 Year change-14.49%
  • Beta0.6147
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of three primary solution categories: Marketing, Reputation and Experience. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. The Company's Experience solutions are provided on a subscription basis via a cross-continuum multi-mode digital platform. Its Reputation solutions allow healthcare organizations to share a picture of their organization.

  • Revenue in USD (TTM)148.58m
  • Net income in USD30.96m
  • Incorporated1997
  • Employees435.00
  • Location
    National Research Corp1245 Q StLINCOLN 68508United StatesUSA
  • Phone+1 (402) 475-2525
  • Fax+1 (402) 475-9061
  • Websitehttps://nrchealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SS Innovations International Inc5.88m-20.94m768.26m239.00--53.73--130.66-0.1293-0.12930.040.08380.3939--2.5324,601.30-140.31-161.38-253.40-449.7612.13-79.79-356.17-495.771.30-52.510.2963-------846.31--159.31--
ALX Oncology Holdings Inc0.00-160.81m775.66m72.00--4.04-----3.74-3.740.003.800.00----0.00-58.58-34.34-66.35-36.47-------7,238.76----0.0592-------30.23--14.30--
Nuvation Bio Inc0.00-75.80m794.35m51.00--1.17-----0.3463-0.34630.002.760.00----0.00-11.72-16.27-11.97-16.65------------0.00------27.25------
CARGO Therapeutics Inc0.00-98.15m800.36m116.00--2.07-----2.37-2.370.009.84------0.00--------------------0.00-------139.67------
Tango Therapeutics Inc36.53m-101.74m812.13m140.00--3.07--22.23-1.08-1.080.38652.480.0871--36.53260,907.10-24.25---27.59-------278.54------0.00--46.93--5.95------
Evolus Inc202.09m-61.69m816.28m273.00------4.04-1.08-1.083.55-0.35781.104.127.63740,238.10-33.62-40.92-45.33-59.7469.5465.43-30.52-80.462.10-3.471.21--35.98--17.10--182.77--
Regenxbio Inc90.24m-263.49m825.39m344.00--2.38--9.15-6.03-6.032.067.080.1283--3.41262,331.40-37.45-16.75-45.96-19.0858.7678.27-291.99-72.06----0.00---19.94-16.216.00---5.59--
Zentalis Pharmaceuticals Inc0.00-292.19m830.94m168.00--1.90-----4.56-4.560.006.180.00----0.00-50.65-47.40-57.28-54.18------------0.00-------23.39--20.76--
Longboard Pharmaceuticals Inc0.00-54.42m831.06m50.00--12.81-----2.39-2.390.001.670.00----0.00-89.72---105.91--------------0.00-------23.84------
National Research Corporation148.58m30.96m832.40m435.0027.7717.2522.585.601.261.266.022.021.18--11.00341,563.2024.4926.2533.8036.7762.3063.2020.8423.95--1,929.640.428655.45-1.974.42-2.580.669521.45-5.29
SAGE Therapeutics Inc91.06m-503.14m838.94m487.00--1.19--9.21-8.40-8.401.5211.730.0916--6.26186,989.70-50.61-21.88-54.64-23.3096.4999.63-552.52-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Pliant Therapeutics Inc1.58m-161.34m843.26m158.00--1.77--533.71-2.75-2.750.02697.900.0037--1.5910,000.00-37.40-33.24-39.82-35.39-----10,211.14-360.29----0.0208---83.69---30.83---16.89--
USANA Health Sciences, Inc.900.45m61.94m876.41m1.80k14.221.7515.980.97333.203.2046.5625.991.462.73--500,250.0010.0316.2312.4921.7580.9881.426.888.963.20--0.00260.00-7.77-4.98-8.02-12.764.86--
89bio Inc0.00-142.19m877.97m70.00--1.60-----2.01-2.010.005.750.00----0.00-35.86-45.50-38.49-49.31------------0.0442-------39.37---36.58--
OPKO Health Inc863.49m-188.86m906.09m3.93k--0.7236--1.05-0.2513-0.25131.151.800.41337.806.89219,718.60-9.03-7.14-10.03-8.1436.8434.42-21.86-13.831.22-15.240.1574---14.01-2.7042.49---10.19--
Data as of May 03 2024. Currency figures normalised to National Research Corp's reporting currency: US Dollar USD

Institutional shareholders

36.78%Per cent of shares held by top holders
HolderShares% Held
Kayne Anderson Rudnick Investment Management LLCas of 29 Feb 20243.19m13.38%
BlackRock Fund Advisorsas of 31 Dec 2023959.03k4.02%
The Vanguard Group, Inc.as of 31 Dec 2023896.21k3.76%
Atlanta Capital Management Co. LLCas of 31 Dec 2023891.84k3.74%
Conestoga Capital Advisors LLCas of 31 Mar 2024784.66k3.29%
Dimensional Fund Advisors LPas of 31 Dec 2023636.40k2.67%
Renaissance Technologies LLCas of 31 Dec 2023373.58k1.57%
Geode Capital Management LLCas of 31 Dec 2023356.31k1.49%
SSgA Funds Management, Inc.as of 31 Dec 2023342.48k1.44%
QV Investors, Inc.as of 31 Mar 2024342.25k1.44%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.